Iovance narrows Q2 loss 57.6% to $99.3M on 65.7% revenue growth; securities litigation advances

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

• high

  Net loss narrowed 57.6% YoY to $47.3M ($0.11/share) in Q2 FY26 as revenue rose 65.7% to $99.3M, driven by Amtagvi® adoption and cost discipline following the August 2025 restructuring.

  MD&A: Financial Results verify on EDGAR →
• high

  Consolidated securities class action filed amended complaint April 2026; company moved to dismiss June 2026. Derivative litigation stayed pending securities case resolution.

  Legal Proceedings verify on EDGAR →
• high

  Company terminated external CMO contract in Q1 FY26, consolidating all manufacturing at the iCTC to improve margins and reduce operating expenses. R&D costs fell 24% YoY.

  MD&A: Operations verify on EDGAR →